As we move forward in the field of cancer immunotherapy, the exploration of TIGIT, VISTA, STING, GITR and TIM-3 within GI cancers expands our arsenal of therapeutic strategies and enhances our understanding of the intricate interactions between cancer and the immune system. The gene discussed is TNFRSF18; the disease is cancer.